An NHS population trial evaluates adding a blood-based multi-cancer screening to standard care and its effects on cancer stage distribution over three rounds.
Key Takeaways
- Trial's primary endpoint showed no significant reduction in combined Stage III and IV cancers.
- Stage IV diagnoses decreased across screening rounds, by 9%, 22%, and 26% respectively.
- Pre-specified secondary analysis found an overall 14% reduction in Stage IV cancers.